EpiVax part of team to develop vaccine for tropical disease classified ‘biothreat’

EpiVax has been named part of a team to develop a vaccine against a bacterium that causes melioidosis, a tropical disease that is often fatal and which the U.S. Department of Defense has identified as a potential “biothreat.”
EpiVax has been named part of a team to develop a vaccine against a bacterium that causes melioidosis, a tropical disease that is often fatal and which the U.S. Department of Defense has identified as a potential “biothreat.”
(Updated, Dec. 19, 4:40 p.m.) PROVIDENCE – EpiVax Inc. is part of a team that has been awarded a $1.87 million grant from Department of Defense’s Defense Threat Reduction Agency to develop an effective vaccine against Burkholderia pseudomallei, a bacterium that leads to melioidosis, a tropical disease that is resistant to many antibiotics and which…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display